Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Invasive Breast Carcinoma|Stage I Breast Cancer AJCC v7|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Triple-Negative Breast Carcinoma
Interventions: PROCEDURE: Axillary Lymph Node Dissection|DRUG: Enzalutamide|OTHER: Laboratory Biomarker Analysis|PROCEDURE: Lymph Node Biopsy|DRUG: Paclitaxel|PROCEDURE: Therapeutic Conventional Surgery
Sponsor: M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)